🇺🇸 FDA
Patent

US 9624233

Compounds for treating pruritic conditions

granted A61PA61P17/04

Quick answer

US patent 9624233 (Compounds for treating pruritic conditions) held by Trevi Therapeutics, Inc. expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Trevi Therapeutics, Inc.
Grant date
Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P17/04